免疫生物标志物在慢性乙型肝炎管理中的应用和挑战

肝脏 ›› 2022, Vol. 27 ›› Issue (11): 1153-1155.

• 前沿、探索与争鸣 • 下一篇

免疫生物标志物在慢性乙型肝炎管理中的应用和挑战

赵彦达, 钟师红, 李咏茵

510515 广州南方医科大学基础医学院(赵彦达);南方医科大学南方医院感染内科,器官衰竭防治国家重点实验室,广东省病毒性肝炎研究重点实验室(钟师红,李咏茵)

收稿日期:2022-11-02 出版日期:2022-11-30 发布日期:2023-01-31
通讯作者: 李咏茵,Email:yongyinli@foxmail.com
基金资助:
国家自然科学基金项目(82022007)

Received:2022-11-02 Online:2022-11-30 Published:2023-01-31

摘要/Abstract

摘要： 慢性乙型肝炎是一种常见的由免疫反应介导的慢性肝脏炎性疾病,近年来关于免疫学相关生物标志物在慢性乙型肝炎中的研究日益增加,这些标志物的出现为评估慢性乙型肝炎治疗效果和患者远期预后提供了价值。由于免疫学检测指标的局限性,目前临床中采用免疫学相关生物标志物对慢性乙型肝炎治疗功效进行评估尚存在诸多挑战。本文对免疫生物标志物应用于慢性乙型肝炎管理的实践与挑战作一综述,以期为慢性乙型肝炎病毒感染的研究提供帮助。

关键词: 慢性乙型肝炎, 免疫, 生物标志物, 治疗

赵彦达, 钟师红, 李咏茵. 免疫生物标志物在慢性乙型肝炎管理中的应用和挑战[J]. 肝脏, 2022, 27(11): 1153-1155.

参考文献

[1] Bertoletti A,Ferrari C. Adaptive immunity in HBV infection. J Hepatol, 2016,64(1 Suppl): S71-S83.
[2] Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol, 2003, 77(1): 68-76.
[3] Fanning GC, Zoulim F, Hou J, et al., Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov, 2019, 18(11): 827-844.
[4] Zhou YZ, Chang YN, He Y, et al. Correlation of qAnti-HBc with antiviral efficacy in children with chronic hepatitis B and exploration of its possible immune mechanism. Zhonghua Gan Zang Bing Za Zhi, 2021. 29(9): 837-843.
[5] Hou FQ, Song LW, Yuan Q, et al. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics, 2015. 5(3): 218-226.
[6] Lu FM, Wang J, Chen XM, et al. Application of the new serum markers in the research and development of innovative hepatitis B drugs. Zhonghua Gan Zang Bing Za Zhi, 2020. 28(8):649-653.
[7] Chi H, Li Z, Hansen BE, et al. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. Clin Gastroenterol Hepatol, 2019,17(1): 182-191.e1.
[8] 杨柳,宋红丽. 乙肝病毒感染慢性化与相关免疫细胞. 实用医学杂志, 2016. 32(06): 1022-1024.
[9] Lunemann S, Malone DF, Hengst J, et al. Compromised function of natural killer cells in acute and chronic viral hepatitis. J Infect Dis, 2014,209(9): 1362-1373.
[10] Sun C,Sun H, Zhang C,et al. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol, 2015,12(3): 292-302.
[11] Li F, Wei H, Wei H, et al, Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice. Gastroenterology, 2013,144(2): 392-401.
[12] Ma SW, Huang X, Li YY, et al. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol, 2012. 56(4):775-781.
[13] Li Y, Tang L, Guo L, et al., CXCL13-mediated recruitment of intrahepatic CXCR5(+)CD8(+) T cells favors viral control in chronic HBV infection. J Hepatol, 2020. 72(3): 420-430.
[14] 高子翔,沈中良,刘晶,等. 细胞因子在慢性乙型肝炎治疗中的研究进展. 临床肝胆病杂志, 2022,38(08): 1710-1715.
[15] Tang L, Chen C, Gao X, et al. Interleukin 21 Reinvigorates the Antiviral Activity of Hepatitis B Virus (HBV)-Specific CD8⁺ T Cells in Chronic HBV Infection. J Infect Dis, 2019,219(5): 750-759.
[16] Yang L, Jia S, Shao X, et al. Interleukin-35 modulates the balance between viral specific CD4(+)CD25(+)CD127(dim/-) regulatory T cells and T helper 17 cells in chronic hepatitis B virus infection. Virol J, 2019,16(1): 48.
[17] Xia M, Liao G, Chen H, et al. Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment. Clin Immunol, 2019,198:31-38.
[18] Maini MK, Boni C, Lee CK, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med, 2000,191(8):1269-1280.
[19] Schuch A, Salimi Alizei E, Heim K, et al. Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8⁺ T cells in chronically HBV-infected patients with low viral load. Gut, 2019,68(5): 905-915.
[20] Aliabadi E, Urbanek-Quaing M, Maasoumy B, et al. Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. Gut, 2022,71(11): 2300-2312.
[21] Le Bert N, Gill US, Hong M, et al. Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection. Gastroenterology, 2020. 159(2): 652-664.
[22] Salimzadeh L, Le Bert N, Dutertre CA, et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest, 2018,128(10):4573-4587.
[23] Bénéchet AP, De Simone G, Di Lucia P, et al. Dynamics and genomic landscape of CD8(+) T cells undergoing hepatic priming. Nature, 2019, 574(7777): 200-205.
[24] Isogawa M, Chung J, Murata Y, et al. CD40 activation rescues antiviral CD8⁺ T cells from PD-1-mediated exhaustion. PLoS Pathog, 2013,9(7): e1003490.
[25] Brümmer LE, Katzenschlager S, Gaeddert M, et al., Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. PLoS Med, 2021,18(8): e1003735.
[26] Tan AT, Lim JM, Bert NL, et al. Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. J Clin Invest, 2021,131(17):e152379.

免疫生物标志物在慢性乙型肝炎管理中的应用和挑战

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	文夏杰, 鲁凤民, 贾继东. 慢性乙型肝炎治愈临床研究进展[J]. 肝脏, 2022, 27(9): 947-949.
[2]	贾昊宇, 杨长青. 肝脏疾病的现代治疗方法[J]. 肝脏, 2022, 27(9): 950-952.
[3]	刘百怡, 饶慧瑛. 丙型肝炎治疗后肝细胞癌的危险因素以及监测方法的研究进展[J]. 肝脏, 2022, 27(9): 956-958.
[4]	杨子新, 王胜兰. α-1抗胰蛋白酶缺乏症相关肝病的诊治研究进展[J]. 肝脏, 2022, 27(9): 959-962.
[5]	李清平, 李硕, 杨雪琴, 张虎, 吴婷, 叶昊. 索拉非尼致肝衰竭1例[J]. 肝脏, 2022, 27(9): 1052-1053.
[6]	孙悦, 孟方圆, 苑广菲, 高沿航. 酒精性肝炎的治疗进展[J]. 肝脏, 2022, 27(8): 849-852.
[7]	卢嘉惠, 张丛楠, 何鹏园, 欧梦党, 黄明星. 富马酸丙酚替诺福韦治疗慢性乙型肝炎合并脂肪肝的疗效及安全性[J]. 肝脏, 2022, 27(8): 858-862.
[8]	张磊, 黄育红, 罗凌, 汪丽萍, 方春华, 冉斌, 李应. 长期抗病毒治疗的慢性乙型肝炎患者血清TIMP-1和M-CSF水平变化[J]. 肝脏, 2022, 27(8): 863-867.
[9]	王利慧, 王荣希, 赵泽源, 郭振凯. 失代偿期乙型肝炎肝硬化患者门静脉血栓形成的临床意义[J]. 肝脏, 2022, 27(8): 874-876.
[10]	刘海霞, 段忠辉, 赖曼, 徐曼曼, 孟庆华, 陈煜. 319例肝病患者持续肾脏替代治疗的管路寿命及影响因素分析[J]. 肝脏, 2022, 27(8): 898-902.
[11]	杨娴, 张静怡, 杨文霞, 唐映梅. EB病毒感染患者肝脏病理及临床特征分析[J]. 肝脏, 2022, 27(8): 903-907.
[12]	周冰清, 黎防, 蒋蓓莉. 恩替卡韦治疗慢性乙型肝炎合并T2DM患者的效果及对糖脂代谢的影响[J]. 肝脏, 2022, 27(8): 925-927.
[13]	高璇, 张翠丽, 曾涛. 自身免疫性肝炎的发病机制与治疗现状研究进展[J]. 肝脏, 2022, 27(8): 928-931.
[14]	周培, 张艳芳. 慢性乙型肝炎低病毒血症的临床研究现状[J]. 肝脏, 2022, 27(8): 932-934.
[15]	杨永生, 邵晨, 张雷. 慢性丙型肝炎伴ANA、LC-1阳性的自身免疫现象1例并文献复习[J]. 肝脏, 2022, 27(8): 941-942.